The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Multicenter phase II study of trastuzumab deruxtecan (DS-8201) for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial.
 
Akihiro Ohba
No Relationships to Disclose
 
Chigusa Morizane
Honoraria - Eisai; Merck Sharp & Dohme; Novartis; Taiho Pharmaceutical; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - Abbvie; Novartis; Taiho Pharmaceutical; Yakult Honsha
Research Funding - AstraZeneca (Inst); Eisai (Inst); J-Pharma (Inst); Merck (Inst); ONO PHARMACEUTICAL (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Makoto Ueno
Honoraria - AstraZeneca; Daiichi Sankyo; Merck Serono; MSD; Nipro Corporation; Taiho Pharmaceutical; Teijin Pharma; Yakult Honsha
Research Funding - ASLAN Pharmaceuticals (Inst); Astellas Pharma; AstraZeneca (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Incyte (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Satoshi Kobayashi
Honoraria - Bayer Yakuhin; Boston Scientific; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Nippon Kayaku; Taiho Pharmaceutical; Teijin Pharma
Speakers' Bureau - Kyowa Hakko Kirin
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Lilly (Inst); Merck Serono (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takara Bio (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Yasuyuki Kawamoto
Honoraria - Chugai Pharma; Daiichi Sankyo; Lilly; Merck; Taiho Pharmaceutical; Takeda
Research Funding - Japan Agency for Medical Research and Development
 
Yoshito Komatsu
Honoraria - Asahi Kasei; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Lilly; Medical Review Co., Ltd.; Merck; Mitsubishi Tanabe Pharma; Moroo Co.; Nipro Corporation; Ono Pharmaceutical; Otsuka; Sanofi/Aventis; Shiseido; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - A2 Healthcare; Astellas Pharma; Bayer Yakuhin; Daiichi Sankyo; Eisai; Incyte; IQvia; Mediscience Planning; Merck Sharp & Dohme; NanoCarrier; Ono Pharmaceutical; Parexel International Corporation.; Sanofi/Aventis; Shionogi; Sumitomo Dainippon; Sysmex; Taiho Pharmaceutical; Yakult Honsha
 
Masafumi Ikeda
Honoraria - Astellas Pharma; Bayer Yakuhin; Dainippon Sumitomo Pharma; EA Pharma; Eisai; Gilead Sciences; Kaken Pharmaceutical; Lilly Japan; MSD; Mylan; Novartis; Otsuka; SERVIER; Taiho Pharmaceutical; Teijin Pharma; Yakult Pharmaceutical
Consulting or Advisory Role - ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly Japan; Micron; MSD; Novartis; Ono Pharmaceutical; SERVIER; Shire; Teijin Pharma
Research Funding - ASLAN Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Eisai (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); NanoCarrier (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Takeda (Inst); Yakult Pharmaceutical (Inst)
 
Mitsuhito Sasaki
No Relationships to Disclose
 
Naohiro Okano
No Relationships to Disclose
 
Junji Furuse
Honoraria - Abbvie; Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; EA Pharma; Eisai; Fujifilm; J-Pharma; Kyowa Hakko Kirin; Lilly Japan; Merck Serono; Mochida Pharmaceutical Co. Ltd.; MSD; Nihon Servier; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Sawai Pharmaceutical Co; Shionogi; Shire; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Eisai; Fujifilm; J-Pharma; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; Otsuka; Shire; Sumitomo Dainippon; Taiho Pharmaceutical; Takara Bio; Yakult Honsha
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); J-Pharma (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); MSD (Inst); NanoCarrier (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Nobuyoshi Hiraoka
No Relationships to Disclose
 
Hiroshi Yoshida
No Relationships to Disclose
 
Aya Kuchiba
Honoraria - Chugai Pharma
 
Gakuto Ogawa
No Relationships to Disclose
 
Kenichi Nakamura
Honoraria - Bayer Yakuhin; Chugai Pharma
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb Japan (Inst); Chugai/Roche (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyorin (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Naoko Matsui
No Relationships to Disclose
 
Yoshiaki Nakamura
Research Funding - Taiho Pharmaceutical (Inst)
 
Wataru Okamoto
No Relationships to Disclose
 
Takayuki Yoshino
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); PAREXEL International Inc. (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst)
 
Takuji Okusaka
Honoraria - Abbvie; AstraZeneca; Bayer; Celgene; Daiichi Sankyo; EA pharma; Eisai; Fujifilm; Lilly; Meiji Seika Kaisha; MSD; Mundipharma; Nippon Shinyaku; Novartis; Ono Pharmaceutical; Pfizer; SERVIER; Shire; Taiho Pharmaceutical; Takeda; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Dainippon Sumitomo Pharma; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); Baxter (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); MSD (Inst); NanoCarrier (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Takara Bio